Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker
- PMID: 40725
- DOI: 10.1002/cpt1979266682
Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker
Abstract
The systemic bioavailability, elimination half-life (t1/2), and plasma concentration--response relationships of pamatolol, a relatively cardioselective beta adrenoceptor blocker, have been measured in healthy subjects. Pamatolol is rapidly and completely absorbed after oral dosing. Elimination t1/2 ranged from 2.9 to 4.6 hr after oral doses and from 2.2 to 5.6 hr after intravenous doses. There was a clear relationship between log plasma pamatolol concentration and sympathetic blockade assessed by reduction of exercise heart rate. Concentration-response curves were essentially identical after oral and intravenous doses. There is no evidence of a first-pass effect, nor is there any evidence of metabolite activity.
Similar articles
-
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.Clin Pharmacol Ther. 1976 Nov;20(5):524-34. doi: 10.1002/cpt1976205524. Clin Pharmacol Ther. 1976. PMID: 10125
-
Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug.Clin Pharmacol Ther. 1978 Aug;24(2):168-74. doi: 10.1002/cpt1978242168. Clin Pharmacol Ther. 1978. PMID: 28193
-
[The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].Pharmazie. 1975 Oct;30(10):673-5. Pharmazie. 1975. PMID: 694 German. No abstract available.
-
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.Clin Pharmacokinet. 1976;1(4):233-63. doi: 10.2165/00003088-197601040-00001. Clin Pharmacokinet. 1976. PMID: 13958 Review.
-
Beta-adrenoceptor blocker toxicity: clinical features and therapy.Am J Emerg Med. 1984 Nov;2(6):518-25. doi: 10.1016/0735-6757(84)90078-0. Am J Emerg Med. 1984. PMID: 6152169 Review.